Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA) at baseline and at 12 and 24 weeks
| WPAI-RA | Baseline, mean (SD) | Week 12, LSM (95% CI) change from baseline | Week 24, LSM (95% CI) change from baseline | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Question administered to all patients | Placebo (N=225) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=226) | Placebo (N=206) | Baricitinib 2 mg (N=222) | Baricitinib 4 mg (N=213) | Placebo (N=141) | Baricitinib 2 mg (N=187) | Baricitinib 4 mg (N=187) |
| Mean (SD) daily activity impairment due to RA administered to all patients at baseline and LSM (95% CI) change from baseline at week 12 or 24 | |||||||||
| Percent activity impairment due to RA | 57 (23) | 58 (25) | 56 (23) | −13 (−16 to −10) | −19** (−23 to −16) | −20** (−23 to −16) | −20 (−23 to −16) | −23 (−27 to −20) | −23 (−26 to −19) |
| Number (%) of patients who were employed at baseline and at baseline and week 12 or 24 | |||||||||
| Questions administered to patients who were employed | Placebo (N=225) | Baricitinib 2 mg (N=229) | Baricitinib 4 mg (N=226) | Placebo (N=83) | Baricitinib 2 mg (N=85) | Baricitinib 4 mg (N=73) | Placebo (N=55) | Baricitinib 2 mg (N=73) | Baricitinib 4 mg (N=66) |
| Employed at time point and baseline, n (%) of patients | 90 (40) | 88 (38) | 76 (34) | 78 (94) | 80 (94) | 70 (96) | 48 (87) | 67 (92) | 61 (92) |
| Mean (SD) presenteeism, work productivity loss, and absenteeism at baseline and LSM (95% CI) change from baseline at week 12 or 24 | |||||||||
| Percentage impairment while working due to RA (presenteeism) | 43 (24) | 46 (26) | 42 (24) | −8 (−13 to −2) | −14 (−20 to −8) | −16* (−22 to −11) | −18 (−25 to −12) | −20 (−26 to −15) | −22 (−27 to −16) |
| Percentage of overall work impairment due to RA (work productivity loss) | 45 (25) | 51 (28) | 44 (25) | −3 (−9 to 3) | −13* (−20 to −7) | −11* (−18 to −5) | −18 (−25 to −11) | −18 (−24 to −12) | −19 (−26 to −13) |
| Percentage of work time missed due to RA (absenteeism) | 8 (20) | 19 (30) | 9 (23) | 4 (−1 to 9) | −1 (−6 to 4) | 2 (−3 to 7) | −4 (−10 to 3) | 1 (−4 to 7) | 1 (−5 to 6) |
*p≤0.05, **p≤0.01 vs placebo.